Teva Stock Could Be Gearing Up for a Rally
Michele Schneider | Sep 12, 2023 03:09AM ET
This week, I covered Teva (NYSE:TEVA), a stock I have talked about a few times, and one, full disclosure, we are positioned in.h2 About the Company/h2
Teva Pharmaceuticals is an international pharmaceutical company headquartered in Israel.
Founded in 1901, Teva is one of the world's largest generic drug manufacturers.
The company specializes in the development, production, and marketing of a wide range of generic and specialty pharmaceutical products.
Teva's generic drugs are typically less expensive alternatives to brand-name medications, which can help make healthcare more affordable for patients and healthcare systems.
In addition to generics, Teva also develops and manufactures specialty pharmaceuticals, including drugs for conditions such as multiple sclerosis, respiratory diseases, and central nervous system disorders.
h2 Teva's Challenges Legally Resolved/h2The company has faced its share of challenges and controversies, including legal disputes related to generic drug pricing and allegations of anticompetitive behavior.
However, one big development TEVA reached a deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ) to settle the criminal price-fixing charges brought against Teva in 2020.
Teva will pay a fine of $225 million over five years, with $22.5 million due each year from 2024 through 2027 and $135 million due in 2028.
The bad news is that this will impact on their bottom line.
The good news is that the case is settled and done with.
The chart is fascinating.
The resistance at 10.00 is clear on the daily chart.
TEVA is one of the few instruments that has handily cleared its July 6-month calendar range high (green horizontal line).
The 50 daily moving average is about to cross or golden cross the 200-DMA and enter a bullish phase.
Since the earnings gap in early August, the price has consolidated.
Our Leadership indicator shows TEVA beginning to outperform the SPY.
Our Real Motion indicator, already in a bullish phase, is not quite at the early August high in momentum so that is why we are waiting for a clearance of the price resistance at 10.00
This is for educational purposes only. Trading comes with risk.
h2 ETF Summary/h2- S&P 500 (SPY) 440 support 458 resistance
- Russell 2000 (IWM) 185 pivotal
- Dow (DIA) 347 pivotal
- Nasdaq (QQQ) 363 support and over 375 looks better
- Regional banks (KRE) Another modern family member struggling here under 44
- Semiconductors (SMH) 150-161 range to watch
- Transportation (IYT) Needs to get back over 247 to look healthier
- Biotechnology (IBB) Compression between 124-130
- Retail (XRT) 62.90 the July calendar range low broke down-along with IYT-2 negative signs
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.